Royalty Pharma plc announced that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia.